SEMAGLUTIDE (Glucagon-Like Peptide-1 (GLP-1))

SEMAGLUTIDE is an agonist of the Glucagon-Like Peptide 1 receptor. It is used in the treatment of Type 2 diabetes. SEMAGLUTIDE is manufactured as 5mg/vial injections which contain Glucagon-Like Peptide-1 (GLP-1) 5mg and excipients.

SEMAGLUTIDE Mechanism of Action

SEMAGLUTIDE acts on the GLP-1 receptor to exert its effects. Once it binds to this receptor, a cascade of events is set in motion which results in the increased production of Insulin, inhibition of glucagon and delay of gastric emptying. The secreted insulin helps to mop up glucose and achieve blood sugar control. It has an advantage over other insulin secretagogues in that they have a lower risk of causing hypoglycemia.

SEMAGLUTIDE Dosage

As directed by the physician.

SEMAGLUTIDE Side Effects

Hypoglycemia, redness or inflammation at the injection site, nausea, vomiting, pancreas or gall bladder disease.

SEMAGLUTIDE Interactions

Beta-blockers, diabetes medications.